

**EMA WORKSHOP:
PREVENTION AND MITIGATION
MEASURES TAKEN BY COMPANIES**

01 JULY 2024



We know that patients are waiting

We face an unprecedented global demand for injectable incretin medicines.

We are committed to supplying Lilly medicines for type 2 diabetes and weight management.

We have taken a vocal, public position to stand against the inappropriate use of our medicines.

We have begun the most ambitious manufacturing expansion in our 148-year history to meet this demand

We are working to meet the unprecedented global demand for injectable incretin medicines

We have prioritised supply for patients already on therapy and issued consistent recommendations that healthcare providers do not initiate new patient starts since September 2022.

We continue to supply all EU markets, maintain supply at agreed levels and have been transparent about our supply challenges.

We have developed different presentations of our newest medicine to improve supply .

We have taken an active and vocal stance against inappropriate use and the dangers of counterfeit and illegally compounded medicines.

Our new manufacturing facilities take time to be fully operational, but are already helping us to increase supply.

We remain committed to supplying Lilly medicines for type 2 diabetes and weight management.



Our investments in manufacturing capacity are beginning to deliver

We continue to make historical investments and add manufacturing and supply capacity around the world.

- **We have invested \$18 billion into growing our manufacturing capacity since 2020**
- **This includes 7 new manufacturing sites in the EU (Ireland and Germany) and the USA**
- **Significantly expanding our existing footprint in France, Ireland, Italy and Spain**

We have doubled our manufacturing capacity to meet global demand for our injectable incretin medicines since 2022.

We remain on track to increase production of our injectable incretin medicines in the second half of 2024 by another 50% compared to the second half of 2023.

We are confident that our investments and efficiency efforts will allow us to keep expanding over the coming years.

We recognize the significant unmet need for patients living with diabetes and obesity across the world and continue to strive to maximize the number of people we can help with our medicines.

Lilly

A MEDICINE COMPANY